Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

Cancer immunotherapies are increasingly combined with targeted therapies to improve therapeutic outcomes. We show that combination of agonistic anti-CD40 with antiangiogenic antibodies targeting 2 proangiogenic factors, vascular endothelial growth factor A (VEGFA) and angiopoietin 2 (Ang2/ANGPT2), i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashyap, Abhishek S., Schmittnaegel, Martina, Rigamonti, Nicolò, Pais-Ferreira, Daniela, Mueller, Philipp, Buchi, Melanie, Ooi, Chia-Huey, Kreuzaler, Matthias, Hirschmann, Petra, Guichard, Alan, Rieder, Natascha, Bill, Ruben, Herting, Frank, Kienast, Yvonne, Dirnhofer, Stefan, Klein, Christian, Hoves, Sabine, Ries, Carola H., Corse, Emily, De Palma, Michele, Zippelius, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2020
Materias:
PNAS Plus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955310/
https://www.ncbi.nlm.nih.gov/pubmed/31889004
http://dx.doi.org/10.1073/pnas.1902145116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955310/
https://www.ncbi.nlm.nih.gov/pubmed/31889004
http://dx.doi.org/10.1073/pnas.1902145116

Ejemplares similares